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A B S T R A C T
Aims: To explore cancer trial coordinators' roles and challenges in administering patient-reported outcome
(PRO) questionnaires, and establish what PRO-speciﬁc training and guidance they received and needed.
Methods: Eligible cancer trial coordinators experienced with PRO assessment from approved Australian sites
participated in an audio-recorded, semi-structured interview (transcribed verbatim). Recruitment continued
until data saturation. Transcripts underwent content analysis.
Results: Twenty coordinators participated (professional training: nursing (n = 12), science/research (n = 4),
both (n = 4)). PRO administration formed a minor component of most (85%) coordinators' roles. PRO ad-
ministration challenges included managing ‘English second language’ participants, participants' companions
who attempted to complete questionnaires, burdensome questionnaires, and balancing their duty of care against
trial requirements. Coordinators reported inconsistencies in PRO administration, which appeared to arise as a
result of confusion and inconsistent or contradictory PRO training. Inconsistencies concerned whether/when
they explained the purpose of PRO assessment, which participants they approached to complete PROs, and
whether they used PRO trial data to inform care.
Coordinators received PRO training from various sources; most commonly study-speciﬁc start-up meetings
(45%) or from colleagues (30%). Two received no PRO-speciﬁc training. Despite the challenges reported, many
(55%) felt they did not need further PRO training.
Conclusion: Trial coordinators receive inconsistent PRO-speciﬁc training and are often unclear how to prioritise
diﬀerent aspects of data quality when faced with everyday challenges, leading to inconsistent methods, missing
data, poor quality data, and even bias. Agreement on how coordinators should prioritise the requirements of
PRO studies is a necessary pre-requisite for the development of much-needed, consensus-based PRO adminis-
tration guidelines.
1. Introduction
Patient-reported outcomes (PROs) provide information about the
impact of disease and treatment on quality of life and symptoms from
the patients' perspective [1]. Within a cancer clinical trial, PRO evi-
dence may be interpreted in the context of survival and other outcome
evidence to inform evaluations of comparative treatment eﬀectiveness,
which ultimately may inform shared-decision making and health policy
[2].
In cancer clinical trials, PRO questionnaires are usually adminis-
tered to the patient or trial participant (for the participant to self-
complete) by a nurse or research team member known variously as a
‘trial coordinator’, ‘clinical research coordinator’, ‘site coordinator’, or
‘research nurse’ [3]. For the purpose of this paper, we refer to the role
as ‘trial coordinator’; reﬂecting the individual/s appointed at each trial
recruiting centre, or ‘site’, who are responsible for ‘PRO administration’:
preparing and providing instructions for participant self-completion of
questionnaires, responding to participant queries, collecting completed
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questionnaires, and sometimes for entering questionnaire data; among
other trial coordination and data collection duties.
Trial data collection methods related to physical examinations,
imaging, laboratory tests, and PRO administration must be standardised
to minimise the risk of bias resulting from inter-observer variability [4].
Standardisation of PRO administration methods is also an important
strategy to minimise the risk of missing PRO data and subsequent
generalisability issues [5]. Key aspects of PRO assessment may easily be
standardised, for example, the choice of PRO questionnaire with which
to compare treatment group outcomes, and the follow-up time points at
which PRO questionnaires are administered. However the extent to
which PRO administration procedures are standardised remains un-
clear. Reviews of PRO aspects of trial protocols suggest that although
the basic aspects of PRO assessment are addressed frequently in trial
protocols, guidance related to PRO administration procedures is often
lacking [6,7]. It is possible that other forms of guidance, for example,
standard operating procedures or staﬀ training have been used to
standardise PRO administration methods, however to our knowledge,
no previous studies have explicitly examined this.
A recent UK study found trial staﬀ working in various clinical trial
populations were dissatisﬁed with the minimal PRO-speciﬁc training
they had received, particularly with reference to handling concerning
PRO responses or participants who become emotional when completing
questionnaires. Only four of these participants worked in oncology, and
the sample was heterogeneous in terms of speciﬁc trial-related duties
[8]. Therefore the extent to which the issues reported in the UK study
exist for cancer trial coordinators is unclear.
The aims of our study were to: understand the various roles of
Australian cancer trial coordinators responsible for PRO assessment,
determine their challenges regarding PRO administration, establish
what training and guidance is typically oﬀered to trial coordinators,
and determine the self-perceived PRO-speciﬁc training needs of trial
coordinators.
2. Methods
2.1. Ethics
Human Research Ethics Committee (HREC) approval was provided
by The University of Sydney (2014/383), Royal Prince Alfred Hospital
(X14-0282), and Royal Brisbane and Women's Hospital (HREC/15/
QRBW/475).
2.2. Participants
Trial coordinators based at approved Australian sites who were re-
sponsible for administering PRO questionnaires in cancer trials and who
had at least 6 months experience in the role were eligible to participate.
In response to an email invitation sent to trial coordinators at each
approved site, volunteers provided written informed consent and were
contacted by phone to conﬁrm eligibility and to schedule an interview.
The email invitation clearly outlined the aims and goals of the research.
None of the participants had previous or existing working relationships
with the interviewer. Participants were aware that the study team was
comprised of specialist PRO researchers, as the roles and position titles
of investigators were described on study information materials.
Recruitment of consecutive, interested trial coordinators continued
until data saturation was achieved. Participants did not receive any
incentives for participation.
2.3. Interview methods
Interviews were semi-structured, allowing key issues to be explored
in further detail or for clariﬁcation [9]. A topic guide was prepared
comprised of three sections: (1) trial coordinator roles and responsi-
bilities, including time spent on PRO assessment and other non-PRO
responsibilities; (2) general procedures for each key stage and aspect of
PRO administration (e.g. consent, discussing PROs with trial partici-
pants, challenges with PRO assessment, and forwarding PRO data to the
sponsor/central trial oﬃce); and (3) training, including what profes-
sional and PRO-speciﬁc training they had received, their perceived
PRO-speciﬁc training needs, and preferred formats of guidance. The
topic guide was discussed as a team regularly and allowed novel ideas
raised in earlier interviews to be discussed in subsequent interviews.
Interviews were conducted over the phone or face-to-face (if location
was feasible), as per participant preference. Interviews were conducted
one-on-one by a trained and experienced interviewer (RMB), as part of
her doctoral research. All interviews were audio-recorded, de-identiﬁed
and transcribed verbatim by an objective, external, professional agency
– therefore we did not require participants to comment on interview
transcripts. No repeat interviews were conducted.
2.4. Analysis
Interview transcripts underwent content analysis; a method en-
abling identiﬁcation, organisation, and interpretation of patterns within
the data [10,11]. Content analysis was appropriate for this study be-
cause we sought a content-sensitive method to synthesise the experi-
ences, processes, challenges and needs of trial coordinator participants
discussed during the interviews, and to quantify the ﬁndings when
meaningful to do so [10]. We sought to present ﬁndings in a descriptive
manner, to increase understanding of the trial coordinator role in the
context of PRO data collection [10]. We acknowledge that the interview
questions were formulated and the data interpreted through a ‘PRO
methodological researcher’ lens, informed by our previous research
ﬁndings, in order to highlight necessary future training topics, metho-
dological and practical areas in need of improvement, and possible
strategies to address these challenges. For transparency, we have pre-
sented quotes to support our interpretation. We have also highlighted
where certain themes or practices were based on only a small number of
interviews for transparency and discuss the broader role of trial co-
ordinators for context.
A coding framework was developed based on an iterative process,
using inductive (bottom-up or “data-driven”) and theoretical (top-down
or “theory-driven”) methods [10–12], the latter based on past metho-
dological work [5,8,13]. Coding was managed using Dedoose software
[14]. RMB reviewed and coded all transcripts in depth and DK checked
the coding framework and application of codes for 20% of the inter-
views. Based on team discussions, the codes were organised into cate-
gories for presentation. All authors agreed on the ﬁnal code structure.
3. Results
3.1. Sample characteristics
Interviews were completed between July 2014 and April 2016.
Twenty participants were interviewed from ﬁve Australian hospitals,
two of which were private centres. The mean interview length was
47 min. Participant characteristics are presented in Table 1.
4. Findings
4.1. Roles and skills of trial coordinators
4.1.1. General roles
Coordinators described multiple responsibilities associated with
trial coordination; commonly including: managing governance issues
for multiple trials, consenting participants, reporting adverse events,
completing case report forms, ensuring clinicians complete required
paperwork correctly, reviewing prospective trial protocols, organising
meetings with other trial coordinators, organising patient appointments
for data collection (scans, blood tests), managing study budgets and
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contracts, liaising with sponsors, and preparing low risk ethics appli-
cations. Trial coordinators who were responsible for other staﬀ ad-
ditionally had human resource responsibilities. In one participating
clinic, but not at others, trial coordinators (who were all trained as
nurses) played an advocacy role, whereby they would attend all the
participants' appointments with the oncology clinician, assist and
prompt the participants to ask questions at those appointments.
4.1.2. PRO-speciﬁc roles
All explained that time spent on PROs was variable, depending on
speciﬁc trial assessment schedules, length of questionnaires, and the
number and types of trial participants enrolled. Seventeen trial co-
ordinators (85%) felt that PRO-speciﬁc tasks formed only a minor part
of their role. The remaining three coordinators explained that trials
they were currently responsible for required more frequent PRO as-
sessment.
“… one of my latest studies, quite a lot of time is spent. I spend probably
about an hour with the patient” Participant 07.
4.1.3. Organisational skills and strategies
All coordinators described a need for organisational skills and pro-
cesses, in relation to PRO assessment. Most had developed independent
systems to ensure PRO questionnaires and other assessments were ad-
ministered according to schedule.
“I have a spreadsheet … a giant list of what's due when and it ﬂags up
and I put it in my calendar as well and in my diary handwritten and on
the computer … having seven studies and all at multiple time points …
quite a lot of things need to be done along with the questionnaires, so
being organised is pretty crucial. There's no way you can keep that in the
top of your head.” Participant 14.
“I'll look through their schedule and see what time point they're in, review
and see if they're due for a quality of life. I'll print it out and get it ready
for the patient, (write) their de-identiﬁed details or study number …. I
tend to leave the date blank because if the patient has a delay or doesn't
turn up it just saves me from having to reprint, …and then put it with all
the rest of their paperwork that I'll need for that visit” Participant 13.
4.1.4. Empathy for and rapport with participants
Coordinators also described the importance of having compassion
and empathy for participants. They noted that developing rapport with
participants and having open communication assisted them to achieve
high PRO completion rates.
“I think just being clear about what's being asked for and, I guess
engaging the patient in that process, being positive, being supportive or
being available if they've got any queries, I think that helps. Usually we
build up a pretty good relationship with the patients, …so by the time we
get to completing the PROs then we've already got a reasonably well
established rapport with the patient …” Participant 10.
“The relationship is very important in terms of compliance, I would have
to say. It makes a big diﬀerence …. I think you just need to try not to be
too clinical in that ﬁrst visit, recognise them as like yourself going through
that experience, or your mother or, you know, your brother, you know
anybody. They're a person and they've got interests like yourself so, I
always ﬁnd that if you can get sort of like a common grounding or some
sort of common interest. It doesn't take a long time to develop a re-
lationship. But if you're there from go, and you're very clinical and you're
only talking about cancer and, you know, well you just don't develop that
relationship I suppose.” Participant 04.
4.1.5. Adapting to participants' needs
Coordinators also explained the importance of being adaptable and
working around the study participants' needs to obtain the required
PRO data.
“I think it's just what you know as a nurse. So the ability to be able to
identify issues with patients and assist them when that's required.
Troubleshooting, I guess …. if you think they're going to have trouble
with it, you can look at other methods of assisting them.… they might be
struggling with the wording and you could help them with that. It could be
timing… If they're not feeling particularly well, reschedule another time”
Participant 06.
4.1.6. Inconsistencies in PRO data collection
4.1.6.1. Discussions regarding PROs at the time of consent. Coordinators
typically were involved in the trial consent process, along with clinician
investigators; however the extent to which coordinators discussed PRO
assessment during consent varied considerably. Most coordinators
would inform participants about the need to complete PRO
questionnaires throughout the trial, although not all coordinators
would go into detail, as they would prioritise the details of the
investigative treatment.
“Before you even consent a patient you like explain the … requirements
of the study. So they're well aware… they enter the study and then one of
the requirements is they do a quality of life questionnaire” Participant
04.
“At the beginning of the consent stage … if there are questionnaires in-
volved in part of the study, um, how frequently the questionnaires are
administered, how involved they are, how long we would expect patient
to take to answer those questionnaires and um, like, depending on how
much information there is at the time and how bombarded the patient
feels, and probably we'd show the patients an example of the ques-
tionnaires as well.” Participant 10.
“Before they consent we kind of just talk about what's involved with the
study, so, you know, that they have bone marrow, or, you know, blood
tests and, and we'd also mention that they have, um, questionnaires in-
volved which they, um, would ﬁll out at, you know, certain periods of
time, which is basically to see how they're doing on the study, so, I mean
it's kind of generalised, we don't go really in deep about questionnaires
…. they're more concerned about invasive procedures or if this drug's
going to work for them” Participant 20.
However some trial coordinators noted they do not mention PRO
assessment at consent stage.
“I would probably leave that up to the PIC [Participant Informed
Consent] provided to the patient. We probably wouldn't discuss it in
detail with the patient, ‘cause they usually have more questions about the
Table 1
Characteristics of the 20 trial coordinator participants.
Characteristic n (%)
Sex Female 19 (95)
Professional training Nursing 12 (60)
Science/Researcha 4 (20)
Both nursing and science/research 4 (20)
Cancer trial context Medical oncology 10 (50)
Haematology 5 (25)
Radiotherapy 4 (20)
Endocrinology 1 (5)
Mean (range)
Participant age 44 years (28–64
years)
Years' experience Since completion of professional
training
19 years (5–34
years)
In trial coordinator role 9 years (1–20 years)
a e.g. Bachelor of Applied Science or Bachelor of Health Informatics.
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treatment side of things and when, how often they'd be coming in and
that sort of thing. Um, it's really only after they've consented that we
would provide information speciﬁcally about the process.” Participant
11.
Explanations about the purpose of PRO assessment also varied in
detail and content. Some explanations were detailed:
“So you say, ‘it important that we have this type of information, for
instance, you know this study drug may work, but there might be another
one that has the same results, but this one may make you considerably a
lot sicker, like vomiting, nausea. So we need to have that reﬂected in how
you're feeling and noted in your questionnaires, so this is why it's im-
portant to do these sorts of things'. So give them sort of an understanding
of why we're doing the questionnaires, otherwise they're thinking ‘oh god,
not another questionnaire’” Participant 6.
Others clearly lacked conﬁdence or knowledge about the purpose of
PRO assessment, which was evident by their hesitance in providing
explanations to participants. One even believed coordinators were not
allowed to speak to participants until the questionnaire had been
completed.
“I just hand them the piece of paper” Participant 01.
“'usually I just ﬁnd them in the wait room … and just, ﬁrst thing, just
hand them the questionnaires, a pen, and a clipboard or the site pad and
just say—um, ‘cause it's really, really hard not to ask how someone is,
‘cause it's just the polite thing to do.”
“Sometimes I might just act busy and say, “I just need to, could you just,
ah, ﬁll out this questionnaire ﬁrst and I'll be right back”. That's my
trick< laughs> . Um, ‘cause otherwise I feel very rude” Participant
15.
4.1.6.2. Timing of PRO assessments. All interviewed trial coordinators
understood that ideally the questionnaire should be administered
before other trial procedures, however the time at which coordinators
reported administering questionnaires varied for both clinic- and
patient-related reasons.
“The clinics will ring you and say that (the patient has) arrived.
(Depending on) how many patients you have on the day, if you're in
another clinic seeing another patient, they might get in to see the doctor
before you get back over there to see them.” Participant 09.
“It's easier for them to have other procedures like a blood test done ﬁrst
because that's at a diﬀerent area - closer to where they enter the hospital
… you don't want to make a patient walk hundreds of metres back and
forth just for the reason of having this PRO done before a blood test.”
Participant 16.
“Say if they're coming for a whole day of chemo, we usually wait till
they're actually settled in (treatment) and everything's a bit calmer,
‘cause they're a bit stressed as they come in, not stressed but, you know,
there's a lot happening… when they're settled in the seat and calm, that's
a good opportunity to give them the quality of life.” Participant 12.
One coordinator explained that she worked collaboratively with the
clinical team to ensure PROs were completed prior to appointments.
“I'll get the clinic to call me when the patient arrives so I'll go and see
them ﬁrst …. The doctors know I'm there to see the patient with them
anyway … So they'll say to me, ‘are you ready to see this patient now?’
… If I'm still doing things, I'll (ask) ‘can you just see someone else ﬁrst?’.”
Participant 10.
One coordinator posted questionnaires to trial participants ahead of
clinic visits for participants to complete at home. This PRO adminis-
tration method diﬀered to what was explained in the trial protocol. The
coordinator felt her process was more streamlined and that it assisted in
reminding participants about their appointments.
“I do that of my own accord because as well as getting the questionnaire
back, it also reminds the patient that they've got a visit coming up”
Participant 17.
4.1.6.3. Checking questionnaires for, and following up, missing
data. Another area where administrative inconsistencies were
particularly evident related to checking completed questionnaires for
missing items. Some coordinators did not check completed
questionnaires at all, believing they were conﬁdential based on past
training. Among those who checked completed questionnaires, the time
at which questionnaires were checked seemed to vary:
“Routinely I will always look at it afterwards, I suppose that's experience
- having had them come back before and them not being completed -
you're more wary the next time to make sure that they're completing them
… If (the patient is) still there I can go back and say, “Oh, you forgot this
page”.” Participant 03.
“… when you're recording it is when you sort of pick it up … It can be
days, it can be a week (later)” Participant 09.
Some acknowledged that procedures were trial-speciﬁc.
“… it would depend on the trial because sometimes the quality of life
forms are conﬁdential and the patient can seal them up in the envelope
after so you don't generally look at them.” Participant 03.
Whether coordinators would follow up missed PRO assessments
varied by the reason assessments were missed. If participant appoint-
ments were rescheduled, coordinators would generally administer PROs
at the revised date. However if the trial coordinator forgot to administer
the PRO, generally they would not follow up.
“If I just forget, which is easy enough to do, I simply document that I
forgot to administer it to the patient and usually just it's noted and I make
sure to do it at the next time point … none of the studies I've ever done
have said, “… just send it out to the patient and the patient can ﬁll it out
and send it back”, ‘cause that sort of negates the purpose of doing it
before the review, because the answers will be completely diﬀerent.”
Participant 13.
Others explained they would strive to achieve 100% completion
rates at all costs. One coordinator's strategy was to inform participants
of the value of PRO assessments, and of trial participants' important and
active role in research:
“… they're actually not a subject in the study, they're a participant …
their input is crucial … I sort of say, “Well it'd be sad not to have this
information after you've been on the study for two and a half years
because it's making it less robust. If we don't receive this information,
(it's) less likely to be used and I'd hate for you to have wasted your time
over a few years.” I wouldn't put it quite a bluntly as that but, you know,
you sort of get the picture that it’s a whole big picture and all these pieces
of the puzzle are important … If they know how important the in-
formation is, they're more likely to contribute … they're not just a
number in a box in a spreadsheet, they're actively part and parcel of a
study ‘till its completion.” Participant 14.
4.1.6.4. Use of PRO trial data to inform clinical care. Coordinators
described inconsistent practices regarding whether questionnaires
were checked for responses that may be concerning or require clinical
action (e.g. high anxiety scores, high pain scores), commonly referred
to as PRO Alerts [13]. Four (20%) coordinators had worked on trials
where formal PRO alert protocols were in place, meaning that
coordinators were asked to check completed PRO questionnaires for
certain item responses exceeding a set threshold and were required to
follow an established action plan in response. Another coordinator
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noted that the central coordinating oﬃce determined whether patient
responses necessitated a response and would contact the trial
coordinator upon reviewing the uploaded PRO data to ensure the
treating clinician was informed.
Five coordinators (all nurses) explained they would check com-
pleted PRO questionnaires of their own volition,
“… I'll discuss that with the patient and say, “You know I really think the
doctor needs to know about this”.” Participant 19.
“I'll ﬂick through and just follow up anything that's really obvious, like
that they've got, they didn't sleep or that they've had really bad nausea”
Participant 11.
4.2. Challenges faced by trial coordinators regarding the administration of
PROs
4.2.1. Concerning PRO data
Managing concerning data, with or without guidance, was a major
challenge for coordinators. One coordinator who had worked on a study
with formal PRO alerts in place noted that initially she felt insuﬃciently
trained and ill-equipped to implement the procedures. However dis-
cussions and troubleshooting with the central trial oﬃce led to protocol
amendments to clarify the procedures and to involve appropriately
trained health professionals to address any arising PRO alerts.
“Their instructions in their trial booklet said that the study coordinators
were supposed to then try and delve deeper with the patient as to as-
certain whether this person was truly depressed … I said, “Well, that's
beyond our clinical scope”, you know, we don't have training for this. I
said I would take that question up with the investigators here, because we
wanted to participate in this study, but I certainly wasn't going to be
counselling somebody on anxiety and depression. Um, so our solution
was that if a patient answered anything other than “Not at all” to the two
questions that were at the end, and the “Better oﬀ dead” one was one of
them, that I would have to refer the outcome to the clinician… and make
a note into our electronic medical record system … This is how it has
been managed … our department policy that we came up with, which
is—study coordinators, that's not something that the study can ask for
you to do, and it should be clinically, you know, paid attention to. So we
always have to wear our clinical hat, even though I'm not a radiation
therapist, I'm not a nurse, I'm not a clinician, um, we still have a clinical
role.” Participant 02.
Other coordinators expressed uncertainty as to whether it was part
of their duty of care to check completed questionnaires for this type of
information, or whether checking would violate the trial participant's
privacy, as they had not received clear guidance on this point.
“I think some (coordinators) think, “Well, should I tell the doctor if I'm
not really supposed to be looking at (the completed questionnaire), it's
supposed to be completely conﬁdential”, but, um, sometimes it is im-
portant that these are brought to the attention of the treating physician.”
Participant 17.
4.2.2. Using PRO data in clinical care
Many trial coordinators also felt that PRO data should be used to
manage trial participant care, as not doing so represented a waste of
valuable information and caused burden to trial participants as they
would then need to repeat their concerns verbally.
“When it's on a paper form we can use that as a tool to help guide the
patient with their review appointment with the doctor … When we're
using the electronic diaries we don't have that option of seeing their re-
sponses and so we can't use that as a tool to guide, or help the patient to
discuss how they feel with a doctor. ” Participant 16.
“When I was a grad nurse, many, many years ago, um, a medical student
came to see one of my patients … and was in with the patient for about
an hour for an assessment and then they left. And I went in to see my
patient and he had really bad chest pain… he was all clammy, and I said
to him, “Why didn't you buzz me? You should've let me know”. His ECG
was really bad. And he said, “I let the medical student know”, and so this
medical student had picked it up as part of their assessment and then just
left … And this patient just assumed that because they'd provided that
information they didn't have to be discerning about how they provided it
all, where it went, do you know what I mean? They'd let somebody know
and that that was important enough for someone to act on. So I've always
remembered that experience and been mindful of patients sharing in-
formation …. you might be the only person that they've let that know …
they shouldn't have to keep telling people in lots of diﬀerent ways if
something's going on … and also they're also managing a lot of in-
formation, so they may not remember again until that night when they get
home and go, “Oh, I forgot to tell the doctor about that”, but it's been
represented on the PRO anyway.” Participant 11.
4.2.3. Needs of the trial vs the patient
The challenge of balancing the needs of the trial versus the needs of
trial participants arose frequently, highlighting the need for some
ﬂexibility in procedures. Although coordinators did their best to adhere
to speciﬁed procedures, they acknowledged that the needs of the par-
ticipant would often necessitate ﬂexibility:
“We're talking about oncology patients here. You've got to give them some
leeway… They will often do (the questionnaire) if they can, but if they're
really unwell and deteriorating, you're not going to push that.”
Participant 06.
“I tell them, “Look, if it ends up being too much you're welcome to drop
out of the study, you can't be forced to stay in it.” … But then we always
sort of say, “Oh if you don't want to come in, would you mind still ﬁlling
in the questionnaires?”, or something like that.… if (patients) were given
the opportunity maybe to drop out for 6 months and say, “Look, could we
maybe pick this up again in 6 months see how you feel or 2 months'
time?”, something like that, they might be feeling better about things and
be happy to recontribute later … if it's a long study and, you know, it's
asking for a huge commitment, you've got to try and be ﬂexible. That can
help with the patient I think.” Participant 14.
“you're not going to pass or try to get someone to complete a ques-
tionnaire if they're crying or, you know, not in a physical state to com-
plete a questionnaire, but, I don't really judge, because you don't know
what's going through that person's mind, they just might be looking dull,
but happy to complete the questionnaire, so I don't judge that.
Unless it's something very obvious, and, you know, don't go there … if a
person is, say, looking physically distressed and has expressed that they
are physically distressed and usually in that case, they are taken in to see
the doctor immediately. You're not going to stop them and say, “Hey, can
you please complete this quality of life now?” No.” Participant 05.
“'there's times that I've had to decide not to give the quality of life to a
patient… and I'd let the monitor know. The patient may have progressed
and they're distressed or there's some psychological sort of stuﬀ going on
there that the doctor's aware of too.It's only happened a couple of times
… I'll make a notation that the quality of life wasn't attended on this visit
… The patient's always your priority” Participant 04.
Others admitted to not oﬀering questionnaires to patients if they felt
trial participants were too sick, yet the participant was still willing to
complete the questionnaire.
“Occasionally I've had such a patient, “Look, we're not going to do the
questions today”, and a patient has surprised me and said, “No, that's ok,
I'll do them” Participant 13.
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4.2.4. Participant and trial coordinator burden
Trial coordinators also described challenges related to PRO study
design and procedures. Coordinators noted that long, repetitive ques-
tionnaires were burdensome to both trial participants and themselves.
Participants would often question the need for, and in some cases refuse
to complete, questionnaires due to their excessive burden.
“I do ﬁnd it annoying that there are some studies that ask for them every
week… especially if it's not two or three pages. Some of them can be, like
seven or eight pages long and when you've got really sick people, it's
completely, I mean, they just in the end refuse.” Participant 17.
““Is this really of any use?”, “Do I have to complete this questionnaire?”,
“What does this really mean?”, “Why do I get this question three times?”,
you know, all those questions that I've had participants ask me”
Participant 02.
“Simple, straight-to-the-point, don't make it too hard, patients are going
through enough.” Participant 04.
“Why is it too long?”, “Why do they have to answer it every time? It's the
same questions every time.”” Participant 08.
Other procedural aspects that burden trial coordinators included
instructions for copying questionnaires or returning questionnaires to
the central oﬃce.
“Then they (sponsor) give them to you double-sided. … if you want to
send it out, send it out single-sided because people only look at one side of
the form. Unless it's a booklet. And then if it's a booklet, it's a pain in the
neck to photocopy. If you can just put that stack of forms in the top of the
sheet feeder, hit the copy button, it's so much simpler than raising the lid
and closing the lid, and raising the lid … [laughs] you get my drift?”
Participant 02.
“The more standardised the approach the easier it is.… I think we've got
10 recruiting studies, if they all have the same (procedures) it's so much
easier to get it all right, rather than this one does this, and this one does
that, this one wants you to photocopy and send, this one says scan and
email is ﬁne” Participant 02.
4.2.5. Challenges with question wording and interpretation
Coordinators noted challenges with the questionnaires themselves.
They noted that questions frequently skipped by patients often reﬂected
a poorly worded or unclear question. Often, trial coordinators are not
given any standardised guidance regarding how to assist participant
queries about question wording, which coordinators felt directly im-
pacted the data collected.
“I think sometimes the questionnaires are designed by people who don't
have a lot of patient contact. Sometimes you need to highlight things. Like
for example, you know, this is, “We want you to complete this as you
how you've been feeling in the last 7 days”” Participant 17.
“I usually say …”question number such-and-such has been missed, you
haven't given a response, is that because you weren't sure how to answer
it, or you didn't want to answer that question?”, and they go, “Oh geez, I
didn't see that one”, or, “Nausea, what does that mean?”” Participant
02.
“If they ask a question it'll generally be about their interpretation of the
wording, or, you know, if they've got it right? So I just say, “Whatever
your interpretation of the wording is, that's the right answer” “
Participant 05.
Trial coordinators were also challenged by questionnaires de-
scribing general issues which may not be related to cancer, as these
questions often confused trial participants.
“they may say “It's asked if my legs feel heavy, well, that's got nothing to
do with my cancer, so how do I answer that?”, and I go, “Well, the
question asks if you have heaviness in your limbs. Do you feel like you
have heaviness in your limbs? You have to answer it; it doesn't say do you
have heaviness in your limbs because of your cancer. So you've just got to
answer them as the questions are posed.” Participant 02.
“(Patients) get a bit worried ‘cause they're thinking, “Well, I'm not getting
pain from this cancer … I'm getting pain ‘cause I have a bad back
anyway” Participant 20.
4.2.6. Participants comments on questionnaires
Two coordinators noted that participants often write comments on
questionnaires, and were unclear how to handle these comments based
on training and guidance provided to them. One of these coordinators
explained how she handled a particularly challenging scenario:
“ (the questionnaire was) asking kind of general questions about your
health and (the patient) wrote comments all over it, “How is this sup-
posed to make me feel better?”, “Why is this important?” … she hasn't
really answered any of the questions. … [at the next visit, after this
coordinator explained the purpose of PRO assessment] she continued on
trial and ﬁlled the rest out.” Participant 07.
4.2.7. Provision of assistance to participants
Trial coordinators also described challenges in providing assistance
to participants. The nature of assistance often needed varied.
Interviewees reported that some participants experience diﬃculty un-
derstanding response scales, whereas others simply require assistance
reading questions due to problems with their vision.
“I might have to explain to some people you need to circle a number that
best suits you now, um, or they need clariﬁcation on, some of them are in
the last week and some of them are within the last 24 hours. I think when
it comes to health care people like to think about way beyond those dates
and that doesn't stick, so, clarifying those two points” Participant 13.
One coordinator believed reading questions to participants was
more transparent and objective than having patients independently
self-complete, as this process would assure her that participants un-
derstood questions as they were intended.
“..they give you their answers straight away and you write it down …
They haven't misinterpreted the way you've said it.(Otherwise) they
might just tick all the same boxes and might not have read it properly”
Participant 06.
Coordinators described challenges with e-PRO technology.
“sometimes they don't work and sometimes you think they worked and
then they didn't work.” Participant 09.
“… particularly again my older patient population they're just not fa-
miliar enough with the technology, and (ask), “How am I meant to do
this? Which button do I press next?” Um, that's (happening) less and less,
but it does just occasionally happen and I just sort of sit with them… I try
to give as minimal assistance as I can so I don't inﬂuence them at all.”
Participant 13.
4.2.8. Language and translation
Another common challenge for coordinators was assessing PROs of
trial participants whose ﬁrst language was not English. Coordinators'
strategies for handling this challenge varied considerably, and included
attempting to explain the meaning of words in English, excluding non-
English speakers, using validated questionnaire translations, and using
interpreters.
“They speak English and they can understand English, but when they're
reading something and some of the questions, the way they're worded, it
trips them up a little bit, they don't quite understand what that word
means, and so I'll explain … what that word is, in the context of the
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question.” Participant 13.
“If they're not understanding, you can word it in another way, …you
know, (rather than) saying ‘we want to know your pain scale’, say ‘we
want to understand, or did you have pain? This one being more hurt, this
one being less hurt’ you know. ‘where is your pain?’ so yeah, and then
they sort of understand.” Participant 06.
“We've got one Chinese lady who doesn't come with anybody and doesn't
understand anything about it, and we don't have translated quality of life
for her, so she just doesn't do it …. I mean, we have enough trouble
getting her, understanding you know, just basic stuﬀ.” Participant 09.
“when you meet them the ﬁrst time for screening or stuﬀ, so you identify
whether they'd be comfortable doing it in English or, like, Mandarin or
Cantonese so, yeah, that's what I try to identify before we start, so I can
organise it or I can have, I can ask for a translated questionnaire from
the sponsor.” Participant 08.
“that probably wouldn't worry me personally because of my nursing
background, we use interpreters and would get interpreter service”
Participant 09.
One coordinator explicitly sought guidance on this issue for a spe-
ciﬁc trial and was not given an answer.
“I raised that question that, what if our patients are not native English
speakers? How do we deal about that? And they don't want us to use
some paper questionnaires, they want it speciﬁcally as electronic diary.
Yeah, they didn't give me a direct answer on that as well.” Participant
08.
Participants' partners or carers often pose a challenge for co-
ordinators if they attempt to complete questionnaires on behalf of the
trial participants (as a proxy reporter; i.e. “reports by someone who is
not the patient responding as if that person were the patient” p25 [1])
in trials where self-report was required. Coordinators noted that often
carers will try to inﬂuence participants' responses, believing they know
better:
“The non-English speaking is another whole category … that's a problem
as far as there's quite a lot of relatives that come in and do it with them
… which I think's ﬁne… except of course when you get the wife that does
it for the patient and the wife says, “But I know what he feels like and I'll
do it”, and they tick it all, and that happens quite a lot. Um, and if it's not
the wife it's the son or somebody or other who speaks better English.”
Participant 09.
“I had a really persistent patient's wife … I had to actually take (the
questionnaire) oﬀ her and say, “Actually there's no wrong answer on the
questionnaire, and you (the patient) just need to ﬁll it out the best YOU
can, um, on your own” … And ah, she said that she just wanted to make
sure that he was doing it right… That's why she needed to answer it, and
then, “So actually there is no right or wrong you just need to, um, ﬁll in
what you can”. And ah, so she kind of, she sat away but she's very, very
keen to get in and just do it for him.” Participant 15.
“ I ﬁnd, um, male patients especially older male patients always seek
their wife's help… It's very hard to try and tell them that they need to do
it themselves ‘cause it seems as though their wives do all of the talking…
and the site pads that can be quite hard with elderly patients, they usually
get their wives to do that too. ” Participant 15.
4.2.9. How the PRO data will be used
Two coordinators explained that feeling as though PRO data col-
lected in previous trials had not been adequately analysed or utilised
presented a challenge for them.
“But if they had looked more clearly at the QOL forms in this particular
study that I'm thinking of, and I'm not going to say what it is, if they had
utilised this tool, which we had collected at all these time points over the
24 months, they would have seen that yeah, their response rate to their
survival with their disease progression and their free survival was exactly
the same, but they could have used the QOL forms … that showed that
their nausea was less, their vomiting was less and their actual QOL was a
lot better on this particular drug. I think it would have been marketable.
… Because everything else from a haematological point of view… bloods
and chemistry, it was all the same… but the way that this particular drug
caused a lot less nausea and vomiting, that's got to have improved QOL.
Now they could really have marketed this (drug) with that.” Participant
06.
“… the sponsors stopped doing it, say after 2 years, although the study
continued, they (stopped requesting) the quality of life outcome … The
study started at 2000 … and that drug is marketed now … and the
patients were asking, “Why aren't they collecting this information?” They
should be collecting data all the way through.” Participant 19.
4.2.10. Back-up personnel
Another key challenge described by three coordinators was mana-
ging PRO assessments for colleagues who were absent, or having col-
leagues ﬁll in for them whilst they were absent. Whilst some sites had
procedures in place to train more than one coordinator to administer
each trial, others did not, resulting in ﬁll-in trial coordinators struggling
to meet the needs of these trials.
“We have at least two people that can back-up on the studies and that's to
cover for, like, if I was sick and then the other person was on annual
leave then hopefully the third person would be here…. we prepare all the
study packs. So if I had three patients due in while I was away, for
instance, I'll just make sure that was all done and we handover so, we
allocate the person that's going to look after the patient on that day, um,
and then we handover to them prior. We tell the patient as well, you
know, that this person's going to be seeing you on that day, um, so it's all
handed over oﬃcially and the staﬀ member that's taking over for me
knows and the sponsor for the study knows that this person's the contact
person while I'm away, so, it's all, it's all worked out in advance.”
Participant 20.
“… I helped out on the study, it wasn't actually my particular study, um,
we just didn't ﬁll those (questionnaires) in at those time points.…There
was probably some (guidance) in the site ﬁle but like I said, I was help—I
was holiday relief for that study so I, no, I didn't get any (training) … (I
was looking after the trial for) 4 weeks … I just conferred with other
colleagues here and left it for her to sort when she got back, basically.”
Participant 18.
4.3. PRO-speciﬁc training and guidance
4.3.1. PRO training received by coordinators
Trial coordinators received diﬀerent levels of training about PROs.
Two reported not having ever received PRO training, 2 attended PRO-
speciﬁc training courses whilst the remaining 16 noted that PROs were
addressed at non-specialist training events, such as study start-up
meetings (n = 9), or training at trials group meetings (n = 3), as
summarised in Table 2. Often trial-speciﬁc training was received
through industry-sponsored trials, and less often through investigator-
initiated trials, which typically had smaller budgets. The most valuable
aspects of training reported by coordinators were communications skills
(n = 8) and PRO administration or practical aspects (n = 7), which
helped improve their day-to-day practices and address common chal-
lenges, such as patient carers completing questionnaires for patients:
“Historically I used to say, “Oh, they've been naughty”, you know, just
joking, “Oh you can't, you can't get involved” you know, “the (responses)
have to be just from her”, … we did some role playing work with the
communication (training) and the person who was playing the part of the
carer felt disregarded when we said those sort of words to them, so that's
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when we worked out a diﬀerent strategy - to say, you know, “what you're
saying is very important, but, um, at the moment just for the purpose of
this form, Mr. X has to ﬁll it out all by himself but, um, I really want to
make sure that you mention it to the doctor, because that's very im-
portant feedback”, you know, that sort of thing.” Participant 12.
4.3.2. Seeking guidance when unclear on procedures
Trial coordinators explained that observing or troubleshooting
problems with colleagues was a less formal training approach, but
helpful for them in addressing everyday issues.
“We'll talk to our other sites that are doing that same trial and say, you
know, “Having diﬃculty with such-and-such, have you got any work
arounds or how are you managing that?” Participant 19.
“If I really get stuck I'll go and speak to my manager … or the lead
investigator and say, “Right, look, I'm having a bit of trouble with this…
and talk it through with them because, you know, they may have had a
bit more experience with this, depending on what their interests are.”
Participant 13.
Others noted they would contact the sponsor directly if they were
unsure how to handle a certain issue or situation regarding PRO as-
sessment. One coordinator suggested that the coordinating centre
should occasionally check in with trial coordinators to determine
whether procedures were clear.
“… I've been meeting with (Project Manager) every so often—just to
smooth things out before we start … It's always, “What do we do about
this? How can we do that?” ” Participant 08.
“I would not hesitate to ring the monitor and have it clariﬁed …. I guess
that it takes up a bit more time. If everything's clearly written in your
protocol then you don't have to do that.” Participant 04.
4.3.3. Self-reported training needs of trial coordinators
Despite the large number of challenges reported by trial co-
ordinators, over half (n = 11, 55%) felt they did not need further PRO-
speciﬁc training or guidance (Table 2). The desired training topics
spontaneously raised by coordinators most frequently included the
theory and purpose of PRO assessment (n = 4, 20%), and handling
concerning PRO data (n = 2, 2%). Regarding the latter:
“Unless we're given training, um, you know, it would be hard for us to
work out, you know, where that trigger point would be .. I guess it's all
about comparing to other responses they've given … to see if there's been
a big change or something. I certainly don't feel like that's within our
(capabilities) …” Participant 12.
One coordinator suggested that training for PRO administration
needed to change focus:
“I think that the training that we receive is all about the paper work and
the boxes and making sure that there's an answer there, um, and not
teaching people how to assist the patients into giving those answers for
themselves.” Participant 19.
Coordinators explained it was often diﬃcult to attend full-day or
oﬀ-site training sessions as they would need someone to cover their trial
coordination responsibilities during their absence or they were too busy
to take leave. Preferred formats of training and guidance diﬀered, with
13 (65%) preferring written guidance, 5 (25%) preferring face-to-face
training, 6 (30%) preferring online modules, and 3 (15%) preferring
trial-speciﬁc training at the study start up meeting, as shown in Table 2.
5. Discussion
Relative to their other trial responsibilities, trial coordinators gen-
erally considered PRO administration a minor but important compo-
nent of their broader role. Most coordinators felt conﬁdent to admin-
ister questionnaires, yet described a range of PRO-speciﬁc challenges
and inconsistencies in day-to-day practices which can adversely aﬀect
the quality and value of PRO data. Coordinators had received contra-
dictory guidance regarding PRO administration and expressed confu-
sion about how to respond to certain challenges, particularly in situa-
tions where they perceived a discord between their duty of care and the
prescribed trial procedures. Although most (90%) coordinators had
received some PRO administration training, there was a lack of con-
sistency in the topics covered, recommended procedures, training
sources, and in the training of back-up staﬀ.
Coordinators described diﬀerences in the types of participants they
approached to complete PROs, whether they oﬀered participants as-
sistance, whether they pursued missed PRO assessments, and how they
managed low-English speaking participants. These issues have been
associated with missing PRO data [5] or selection bias [4] in previous
studies. Some coordinators deviated from scheduled timings of PRO
assessment, which may lead to uninformative or poor quality data if the
timing of administration fails to capture the impact of treatment (e.g.
toxicities, palliative beneﬁt), or if the participant receives information
about their treatment outcomes before PRO completion, causing the
participant to interpret their outcomes and respond diﬀerently. Incon-
sistencies in how, when, and whether coordinators explained the pur-
pose of PRO assessments were also reported, which could cause trial
Table 2
Training received and perceived training needs of 20 trial coordinators.
Nursing
background
n = 12
Research
Trained
n = 4
Both
n = 4
Training received - source
PRO-speciﬁc training course 1 1 0
PRO training covered in other
coursea
Study-speciﬁc training 5 3 1
Training from colleague 3 1 2
CCTG training 0 2 1
Communication training 1 2 0
Good clinical practice
training
2 0 0
Degree 1 0 0
No PRO training 0 2 0
Most helpful aspect of PRO training receiveda
Communication with patients 5 2 1
Practical/PRO administration 4 2 1
Theory (purpose of PRO
assessment)
2 1 1
Database (e.g. data entry) 0 0 1
None expressed 1 0 0
Perceived training needs
Theory (purpose of PRO
assessment, application of
PRO results)
2 0 2
Concerning PRO responses (e.g.
high self-reported anxiety)
1 1 0
Providing assistance to trial
participants
0 1 0
Communication 0 0 1
English second language
participants
1 0 0
None 8 2 1
Preferred format of PRO-speciﬁc guidancea
Face-to-face or over the phone 2 1 2
Online modules/downloadable
presentations
4 2 0
Written guidance (e.g. protocol,
coordinator manual, summary
sheet, etc)
9 3 1
Start-up meetings 2 1 0
No preference 1 0 1
a Trial coordinators may have noted more than one preference or category.
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participants to incorrectly assume their PRO responses inform their
care, or to question the importance of completing questionnaires. This
raises ethical concerns as it demonstrates that some participants are not
fully informed about the nature of their research participation.
Similar to previous research [8], some coordinators reported using
PRO responses to inform clinical care, even in the absence of guidance.
This may be problematic if oﬀ-protocol interventions (e.g. psychosocial
referrals) are administered based on PRO responses (e.g. high patient-
reported anxiety) for some trial participants and not others, without
being formally recorded, where these co-interventions impact the pa-
tient outcomes assessed as part of the trial (i.e. co-intervention bias
[8,15]). Other coordinators reported uncertainty as to whether they
should act on concerning PRO responses. Some felt that PRO assessment
may oﬀer the only opportunity for participants to disclose their health
concerns, therefore they felt some responsibility to review and act on
PRO data.
Generally, coordinators considered their roles as a ‘researcher’ and
‘caregiver’ to be complementary or synergistic, for example many co-
ordinators felt that developing good rapport with participants and
taking time to explain PRO assessment led to higher PRO completion
rates. However in a ﬁnding similar to that reported by Kyte [8] co-
ordinators often felt they were juggling between providing best stan-
dard of care for the participant, their highest priority, (which involves
responding to any concerns arising from PRO assessment, being ﬂex-
ible, and providing assistance when needed) and their research re-
sponsibilities (which involves standardising methodology).
It was apparent that coordinators were often unclear how to
prioritise PRO-speciﬁc requirements of the trial. Is the need for com-
plete data more important than the need to allow participants to in-
dependently self-complete questionnaires? Is it acceptable to explain
the meaning of certain words in questionnaires if the participant clearly
does not understand, at the risk of potentially inﬂuencing their re-
sponse? When does encouragement to participate cross the line into
coercion? Should coordinators act on concerning PRO responses if re-
sponses are not meant to inform patient care? These problems are po-
tentially exacerbated by conﬂicting information oﬀered (or not oﬀered)
in PRO training and guidance, and diﬀerent practices across trials. Such
inconsistencies in guidance have caused confusion among trial co-
ordinators as to what constitutes best practice and how they should go
about their work. The ﬁndings that: (1) the most common form of PRO
training received was study-speciﬁc; and (2) more coordinators re-
ceived PRO training from colleagues than at dedicated PRO sessions,
represents the likely sources of confusion, highlights the importance of
developing standardised PRO administration training for implementa-
tion across trials, and explains the variation in practices and training
needs.
Before consistent PRO administration practices can be developed,
there is a need for PRO research methodologists and stakeholders to
achieve consensus on a hierarchy of priorities in PRO data quality.
Clearly the PRO administration process is not straightforward.
Participants diﬀer in terms of literacy levels, functional abilities, se-
verity of symptoms and toxicities, and their need for reassurance or
assistance from trial coordinators. Coordinators highlighted that the
need to adapt to trial participants' needs often means that trial guidance
is not precisely followed. Therefore rather than simply prescribing a list
of procedures, future training must equip coordinators with the
knowledge and conﬁdence required to logically prioritise how to re-
spond to common administrative challenges. For example, based on a
plethora of evidence demonstrating the problems associated with
missing PRO data [16–18], we argue that complete data is of a higher
priority than ensuring that participants independently self-complete
questionnaires. Accordingly if faced with a situation where a partici-
pant requires assistance (e.g. someone to read the questions and record
responses), or requires an explanation of a particular question in order
to complete the questionnaire, we argue that this should be oﬀered in
favour of avoiding missing PRO data.
To complement such training, those developing the trial protocol
must pre-empt these challenges and design trials to accommodate
participants' needs, in line with the forthcoming Standardised Protocol
Items for Randomised Trials (SPIRIT)-PRO Extension [19]. Trial in-
vestigators should discuss which language groups are commonly re-
presented at recruiting sites and determine whether validated language
translations are available. Many of the most commonly used cancer
PRO questionnaires oﬀer validated translations [20–22]. This practice
would avoid any selection bias from exclusion of non-English speaking
participants or from variation in access to interpreters. Furthermore,
trial investigators should minimise trial participant burden associated
with lengthy or poorly developed questionnaires. Coordinator burden
could also be reduced by avoiding cumbersome data entry procedures.
A potential barrier to the training approaches described above is the
ﬁnding that 55% coordinators felt they did not need further PRO
training, despite reporting challenges and engaging in suboptimal and
unstandardized practices. Coordinators who feel they do not need fur-
ther training are unlikely to attend PRO training courses unless man-
dated. The training needs evident from these interviews are vaster than
coordinators' self-reported training needs. Our ﬁndings suggest co-
ordinators would generally beneﬁt from training in PRO data quality,
communication skills, the importance and purpose of PRO assessment,
responding to participants' PRO-related queries, strategies for avoiding
missing PRO data, and the importance of adhering to standardised PRO
administration methods. Coordinators who reported PRO training
needs recommended very short courses to accommodate busy sche-
dules, with supporting written guidance which they could refer back to.
Trial sponsors have a responsibility in line with good clinical practice
guidelines to ensure coordinators are adequately trained to perform
their duties [23]. Back-up coordinators should routinely be trained to
stand in for absent trial coordinators to avoid missing PRO data. Po-
tentially information gained through these interviews can be used to
deliver training in innovative ways, for example by targeting and
training trial coordinator “leaders” who are approached for informal
“training” sessions, or by delivering more detailed PRO training pre-
sentations at trial start-up meetings. Further research is needed to de-
termine the most feasible and preferred format of future, consensus-
based PRO guidance, as preferences were inconsistent in this study.
5.1. Strengths and limitations
To our knowledge, this is the ﬁrst study exploring the realities of
PRO assessment for cancer trial coordinators and how PRO assessment
ﬁts in the context of their broader role. Coordinators represented ﬁve
Australian cancer trial recruiting sites and had varying levels of ex-
perience with PROs. The participant representation in our study was
similar in terms of sex, professional training and overall duties as re-
ported in a previous survey of Australian trial coordinators [3]. We
acknowledge that the issues raised in these interviews may not reﬂect
the issues experienced by all cancer trial coordinators, however there
were key similarities to Kyte's ﬁndings from 26 UK trial staﬀ [8]. We did
not explicitly ask whether the coordinators were describing interna-
tional or local trials, which is a limitation of this study. However all of
these coordinators work at sites where international trials are con-
ducted.
6. Conclusions
Trial coordinators are at the coalface of PRO data collection and
their role is of upmost importance in delivering high-quality and va-
luable PRO data. Ensuring that coordinators understand the impact of
their PRO administration practices is key to successful implementation,
and this can only be achieved through further education. Our ﬁndings
highlight the importance of providing clear, consensus-based PRO-
speciﬁc guidance and training to trial coordinators and to empower
coordinators with the knowledge needed to respond to various PRO-
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speciﬁc challenges based on a clear hierarchy of priorities for PRO data
quality. Further collaborative research co-designed by trial co-
ordinators, trialists, and PRO specialists is needed to determine how
best to implement such training, particularly for experienced trial co-
ordinators.
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